Complain about a product or service

Lab Reported Close To AIDS Vaccine

March 9, 2007

• New Vaccine First To Show Effectiveness In Preventing HIV • Anonymous E-mails Could Reduce STDs • FDA Approves New HIV Drug • HIV/AIDS Growing Rapidly Among Seniors • Lab Reported Close To AIDS Vaccine • Court Halts Sales of HIV/AIDS Home Test Kit --- • Local AIDS Resources

A small laboratory in Atlanta has been quietly working on a vaccine against the AIDS virus, and says it has achieved a breakthrough that could lead to a vaccine against the killer disease within the next five years.

GeoVax Labs, Inc., on the campus of Emery University, recently reported successful results from a preclinical trial using GeoVax's vaccines for the therapeutic treatment and prevention of AIDS in non-human primates. The company says the data demonstrate the effectiveness of GeoVax's DNA/MVA vaccines in controlling the Simian ("SIV") AIDS virus through immune responses raised by the vaccines.

In light of the results, the company says it has preliminary plans to conduct human therapeutic studies utilizing GeoVax's vaccines. In the recent trial, two monkeys were infected with the SIV AIDS virus and then placed on drug therapy. Thereafter, once early drug therapy had temporarily reduced virus levels, the monkeys were vaccinated with the SIV version of GeoVax's DNA/MVA vaccines.

Six weeks after vaccination, drug treatment was discontinued. The SIV virus levels temporarily rose in the vaccinated individuals, but were later "controlled" (reduced to much lower levels) by immune responses raised by the vaccines.

The reduction of virus levels in the blood stream of these AIDS virus-infected non-human primates has continued for more than a year to date, researchers say.

They add that vaccination with the GeoVax DNA/MVA vaccines has curtailed the development of AIDS and its associated debilitating effects, resulting in healthy, asymptomatic individuals. The monkeys have gained weight and have not required any additional drug therapy.

"The results of this trial demonstrate the long-term promise of our vaccines in treating HIV-AIDS," said Don Hildebrand, CEO of GeoVax Labs. "Our preclinical trials, coupled with encouraging data from two ongoing human trials, help validate the science behind our vaccines and provide the impetus for accelerating the planning of Phase II human trials for our preventive vaccines."

The ability to vaccinate those already infected with the AIDS virus, thereby inhibiting the virus' progressive and debilitating effects, would allow individuals to fight off normal infections, live longer and maintain a more normal lifestyle. The company says that such a vaccine, if approved for distribution, would be considerably more cost-effective and without the same side effects associated with current drug treatment programs.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.